A method for treating a metabolic disorder associated with abnormal bodyweight in a subject is provided, the method including administering to the subject an effective amount of a compound that modulates phosphatidylinositol 5-phosphate 4-kinase beta (PI5P4Kβ) activity, wherein a PI5P4Kβ inhibitor is administered when the subject suffers from a metabolic disorder associated with an underweight bodyweight; and wherein a PI5P4Kβ agonist is administered when the subject suffers from a metabolic disorder associated with an overweight or obese bodyweight. Also provided herein are methods of increasing meat quality and/or yield in livestock or domesticated poultry by administering to an animal an effective amount of a PI5P4Kβ inhibitor, and genetically engineered animals having a substitution in PI5P4Kβ that reduces its GTP-sensing activity.

The present invention relates to a recombinant bacterium genetically modified to produce anthranilic acid and being able to grow in a culture medium lacking tryptophan. It also relates to a method for producing anthranilic acid using said recombinant bacterium.

The present application relates to a glutamine-hydrolyzing GMP synthase variant and a method for producing a purine nucleotide by using the same.